Boston University Chobanian & Avedisian School of Medicine

Jolly Good Inc. Establishes North American Subsidiary: Joint Development of Medical VR for "Apple Vision Pro" with U.S. Experts

Retrieved on: 
Mercredi, novembre 1, 2023
A Jolly Good Fellow (novel), Post-traumatic stress disorder, Anxiety, VR, Cognitive behavioral therapy, Johns Hopkins University, University of Oxford, Chronic pain, United States Department of Veterans Affairs, Boston University Chobanian & Avedisian School of Medicine, SCI, Veterans' affairs, QOL, Veteran, University of Bath Department of Psychology, Opioid use disorder, Research, Chūō-ku, State, Death, PTSD, Quality of life, Learning, Feel Good Inc., Psychology, Boston University School of Public Health, Teaching, Boston University, Apple, Pain, DSM-IV codes, Eye, Opioid, CBT, Cancer, Pain management, Behavioral medicine, Patient, Doctor of Philosophy, Poultry farming, Video game, Nursing, Pharmaceutical industry, Dentistry, Neuroscience

TOKYO, Nov. 1, 2023 /PRNewswire/ -- Jolly Good Inc. (Chuo-ku, Tokyo, CEO: Kensuke Joji, hereinafter referred to as Jolly Good), which develops and provides medical VR, announces that it has established a North American subsidiary with a view to further business expansion in North America.In North America, we will also focus on development for spatial computing, including "Apple Vision Pro" (*1), in both its digital therapy VR and medical education VR businesses.

Key Points: 
  • Chronic Pain Experts
    TOKYO, Nov. 1, 2023 /PRNewswire/ -- Jolly Good Inc. (Chuo-ku, Tokyo, CEO: Kensuke Joji, hereinafter referred to as Jolly Good), which develops and provides medical VR, announces that it has established a North American subsidiary with a view to further business expansion in North America.
  • In North America, we will also focus on development for spatial computing, including "Apple Vision Pro" (*1), in both its digital therapy VR and medical education VR businesses.
  • Opioid abuse and addiction are currently a major social problem in the United States, and many people who take them experience chronic pain.
  • Through this experience, we aim to provide medical education and mental illness treatment using live-action 360-degree video, which is a feature of Jolly Good.

Odyssey Therapeutics Appoints Jeremy Sokolove, MD as Chief Medical Officer

Retrieved on: 
Mercredi, octobre 4, 2023
Biotechnology, Pharmaceutical, Health, Oncology, Odyssey, Abstract, GSK, Bachelor of Science in Human Biology, University, Boston University Chobanian & Avedisian School of Medicine, Emergency medicine, Biochemistry, Internal medicine, Upadacitinib, Lead, Multimedia, Rheumatology, Rheumatoid arthritis, Boston University School of Public Health, Stanford University School of Medicine, Medical research, Vaccine, Division, AbbVie, VA Palo Alto Health Care System, Faculty, Immunology, Pharmacology, Therapy, Boston Medical Center, Giant cell arteritis, Stanford University Medical Center, Inflammation, Pharmaceutical industry, Nursing, Science

Odyssey Therapeutics, Inc. , a biotechnology company pioneering next-generation precision immunomodulators and oncology medicines, today announced the appointment of Jeremy Sokolove, M.D., as chief medical officer.

Key Points: 
  • Odyssey Therapeutics, Inc. , a biotechnology company pioneering next-generation precision immunomodulators and oncology medicines, today announced the appointment of Jeremy Sokolove, M.D., as chief medical officer.
  • In this role, Dr. Sokolove will develop, lead and drive the development strategy and execution of all Odyssey’s clinical assets.
  • View the full release here: https://www.businesswire.com/news/home/20231004996667/en/
    Jeremy Sokolove, M.D., Chief Medical Officer of Odyssey Therapeutics, Inc. (Photo: Business Wire)
    “As the newest member of our executive leadership team, Dr. Sokolove’s medical expertise and background in the biopharmaceutical industry will be critical to the success of our clinical development programs and achieving our corporate goals,” said Gary D. Glick, Ph.D., founder and CEO of Odyssey Therapeutics.
  • “It’s an exciting time to join Odyssey as the organization transitions to a clinical-stage biotechnology company,” said Dr. Sokolove.

Klogenix’ pioneering research on age-related diseases and longevity gene Klotho finds new home at ADvantage Therapeutics, Inc.

Retrieved on: 
Lundi, octobre 2, 2023
Ignition, Bachelor of Science, Boston University Chobanian & Avedisian School of Medicine, Doctor of Philosophy, Harvard University, Pathology, Ageing, Quality of life, Cure, Research, Alzheimer's disease, Multiple sclerosis, Experiment, Advantage, Science, Boston University School of Theology, Biochemistry, Organization, Patient, Immune system, Knowledge, Zenith, DSM-IV codes, Hospital, Pharmacology, Therapy, ALS, NIH, Vienna Biocenter, Caregiver, Disease, Pharmaceutical industry, Vaccine, Tel Aviv University, Neuroscience, Brigham, Klotho, Biology

Dr. Abraham, a distinguished luminary in the fields of Alzheimer’s disease and aging, brings her wealth of knowledge and pioneering work on the Klotho protein to the forefront of ADvantage’s strategic vision.

Key Points: 
  • Dr. Abraham, a distinguished luminary in the fields of Alzheimer’s disease and aging, brings her wealth of knowledge and pioneering work on the Klotho protein to the forefront of ADvantage’s strategic vision.
  • ADvantage Therapeutics Inc. is currently entering confirmatory Phase 2b clinical trials with its AD04 Alzheimer’s drug candidate, developed at its labs at the Vienna, Austria, BioCenter.
  • Commenting on her new role, Dr. Abraham stated, “Through ADvantage Therapeutics’ pioneering compound AD04, and our exploration of the Klotho protein's applications, we are at the forefront of redefining approaches to combat Alzheimer’s disease and the aging process.
  • ADvantage Therapeutics, Inc. believes AD04™ stimulates and/or regulates the immune system to reduce Alzheimer’s pathology.

ADvantage Therapeutics Welcomes Esteemed Expert in Alzheimer’s Disease and Klotho Protein, Carmela Abraham, Ph.D. as Chief Science Officer

Retrieved on: 
Lundi, octobre 2, 2023
Ignition, Boston University Chobanian & Avedisian School of Medicine, Rejuvenation, Doctor of Philosophy, Ageing, Cancer, Cure, Research, Alzheimer's disease, Experiment, Multiple sclerosis, Harvard University, Messenger, Advantage, Science, Boston University School of Public Health, Biochemistry, Organization, Patent, Patient, DSM-IV codes, Zenith, Hospital, Therapy, Pharmacology, ALS, NIH, Kidney disease, Pharmaceutical industry, Tel Aviv University, Neuroscience, Brigham, Biology

Dr. Abraham, a luminary in the fields of AD and aging, will complement ADvantage’s efforts to extend healthspan by delivering proprietary klotho-encoding mRNA.

Key Points: 
  • Dr. Abraham, a luminary in the fields of AD and aging, will complement ADvantage’s efforts to extend healthspan by delivering proprietary klotho-encoding mRNA.
  • As part of this development, ADvantage Therapeutics has acquired important intellectual property assets including four patent applications from Klogenix, which Dr. Abraham co-founded with Menachem Abraham.
  • Dr. Abraham has dedicated her career to unraveling the intricacies of aging and Alzheimer’s disease.
  • Her groundbreaking work has shown that elevating klotho levels can enhance outcomes in mouse models of Alzheimer's disease, multiple sclerosis, and ALS.

Dr. Rhoda Au Receives Prestigious Melvin R. Goodes Prize for Excellence in Alzheimer's Drug Development

Retrieved on: 
Mercredi, septembre 20, 2023
Fillit, Cognition, Inauguration, University, Marsha, Alzheimer's Drug Discovery Foundation, Ageing, Neuroscience, MBA, Research, Vanderbilt University, Doctor of Philosophy, Biomarker, Assistant, Boston University Chobanian & Avedisian School of Medicine, Tablet, Biochemistry, Molecular biology, Department of Pharmacology, University College London, Dementia, MD, Patient, Wake Forest University School of Business, Drug development, Biology, Diagnosis, Entrepreneurship, Digital, Disease, Pharmaceutical industry, Medical imaging, Alzheimer's disease, Anatomy, Pharmacology

NEW YORK, Sept. 20, 2023 /PRNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) has presented Rhoda Au, PhD, MBA, Professor of Anatomy and Neurobiology at the Boston University Chobanian and Avedisian School of Medicine, with the 2023 Melvin R. Goodes Prize for Excellence in Alzheimer's Drug Development for her pioneering work with digital biomarkers. The annual award honors prominent scientists who are recognized for their work transforming the Alzheimer's clinical trial space and was presented at the Ninth Annual Melvin R. Goodes Prize Luncheon.

Key Points: 
  • The annual award honors prominent scientists who are recognized for their work transforming the Alzheimer's clinical trial space and was presented at the Ninth Annual Melvin R. Goodes Prize Luncheon.
  • Au is the first researcher with work focused on diagnostic technologies to receive the Goodes Prize.
  • Au and her team is used to create digital profiles that can differentiate between people with stable cognition, cognitive decline, and dementia.
  • Au and our past winners today, it is easy to imagine that the next big breakthrough comes right here, through the ADDF and the Goodes Prize."

Foresite Labs Welcomes Dr. David Weinreich as Operating Partner

Retrieved on: 
Jeudi, août 10, 2023
Biotechnology, Pharmaceutical, Health, Columbia University, Amgen, BS, Boston University Chobanian & Avedisian School of Medicine, Foresite Capital, Head, Interline, MBA, COVID, Bayer, Georgetown University, Computer, Boston University School of Public Health, MD, Patient, Computer engineering, Angiogenesis, Knowledge, Ichneutica inscripta, Therapy, Labs, Pharmaceutical industry, Regeneron Pharmaceuticals

Foresite Labs today announced the appointment of David Weinreich , MD, MBA, as an operating partner.

Key Points: 
  • Foresite Labs today announced the appointment of David Weinreich , MD, MBA, as an operating partner.
  • David joins Foresite Labs from Regeneron , where he was the executive vice president and head of global clinical development.
  • “David’s experience and proven results in leading the development and delivery of innovative medicines to patients in multiple therapeutic domains will be essential to our work at Foresite Labs,” said Dr. Vikram Bajaj, co-founder and CEO of Foresite Labs.
  • “Foresite Labs remains focused on putting patients first and creating new and impactful solutions to challenging medical conditions,” said David Weinreich, operating partner at Foresite Labs.

Viracta Therapeutics Appoints Darrel P. Cohen, M.D., Ph.D. as Chief Medical Officer

Retrieved on: 
Lundi, août 7, 2023
Duke University Hospital, Drug development, Boston University Chobanian & Avedisian School of Medicine, Microbiology, Pharmacia, Doctor of Philosophy, Crizotinib, Clinical trial, CMO, Boston University School of Public Health, Patient, Georgetown University Medical Center, SAN, Internal medicine, Cell, Sanofi, Jazz Pharmaceuticals, Bone marrow, Therapy, EBV, Pharmaceutical industry, Medicine, Pfizer

SAN DIEGO, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced the appointment of Darrel P. Cohen, M.D., Ph.D. as Chief Medical Officer (CMO), effective immediately.

Key Points: 
  • SAN DIEGO, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced the appointment of Darrel P. Cohen, M.D., Ph.D. as Chief Medical Officer (CMO), effective immediately.
  • Dr. Cohen will oversee the clinical development and regulatory advancement of Nana-val in Epstein-Barr virus (EBV)-associated malignances, contribute to the strategic expansion of Viracta’s pipeline, and serve on the Executive Leadership Team.
  • Prior to this, Dr. Cohen was CMO at Biosight Pharmaceuticals and Head of Clinical Development at EUSA Pharma.
  • and Ph.D. degrees in Medicine and Microbiology from Boston University School of Medicine, trained as a resident in Internal Medicine at Georgetown University Medical Center, and completed a fellowship in hematology/oncology at Duke University Medical Center.

Avoiding the Unpleasant Side Effects of ED Drugs

Retrieved on: 
Vendredi, juillet 28, 2023
NIDDK, Cleveland Clinic, Mayo Clinic, Headache, Boston University Chobanian & Avedisian School of Medicine, Rash, Diarrhea, Hearing loss, COVID-19, Tadalafil, Ageing, Quality of life, Research, Libido, Back pain, Kidney, Dizziness, National Institute of Diabetes and Digestive and Kidney Diseases, Male, Tribulus terrestris, Erectile dysfunction, Digestive, ED, Skin, Dietary supplement, Nursing, Sildenafil

NIDDK (the National Institute of Diabetes and Digestive and Kidney Diseases) puts the number at 30 million men .

Key Points: 
  • NIDDK (the National Institute of Diabetes and Digestive and Kidney Diseases) puts the number at 30 million men .
  • The only problem is that often the solution proposed is to take strong ED medications.
  • Harvard Health reports that ED drugs can leave men with headaches, upset stomachs, rashes, dizziness, diarrhea, and even vision problems.
  • The plethora of side effects undoes much of the positive elements that ED drugs can provide to a man’s quality of life.

Cumulus Neuroscience Presents Data at AAIC 2023 Annual Meeting and Technology and Dementia Preconference

Retrieved on: 
Lundi, juillet 17, 2023
Communication, University, Clinic, Sleep, Data collection, Bristol Myers Squibb, Boston University, Biomarker, Language, CNS, Wakefulness, Trial of the century, Amel Association International, Doctor of Philosophy, Dementia, MD, Patient, Collection, EEG, Amnesia, Confusion, Neurology, Personality, Boston University Chobanian & Avedisian School of Medicine, AD, Health, Function (mathematics), Memory, Conference, Behavior, Medical imaging, Medical device, Alzheimer's disease, Medicine, Cumulus cloud

BELFAST, Northern Ireland and CAMBRIDGE, Mass., July 17, 2023 /PRNewswire/ -- Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data, presented interim data from their real-world feasibility study CNS-101 at the Alzheimer's Association International Conference 2023 in Amsterdam, Netherlands.

Key Points: 
  • BELFAST, Northern Ireland and CAMBRIDGE, Mass., July 17, 2023 /PRNewswire/ -- Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data, presented interim data from their real-world feasibility study CNS-101 at the Alzheimer's Association International Conference 2023 in Amsterdam, Netherlands.
  • Purely digital markers are scalable but lack objectivity," said Brian Murphy, PhD, Founder and Chief Scientific Officer of Cumulus.
  • Importantly, the remote data captured in this study was of similar quality to data generated using traditional methods in house at Boston University."
  • Dr. Budson and his team receive funding and other resources from Bristol Myers Squibb and Cumulus Neuroscience.

Cumulus Neuroscience Presents Data at AAIC 2023 Annual Meeting and Technology and Dementia Preconference

Retrieved on: 
Lundi, juillet 17, 2023
Communication, University, Clinic, Sleep, Data collection, Bristol Myers Squibb, Boston University, Biomarker, Language, CNS, Wakefulness, Trial of the century, Amel Association International, Doctor of Philosophy, Dementia, MD, Patient, Collection, EEG, Amnesia, Confusion, Neurology, Personality, Boston University Chobanian & Avedisian School of Medicine, AD, Health, Function (mathematics), Memory, Conference, Behavior, Medical imaging, Medical device, Alzheimer's disease, Medicine, Cumulus cloud

BELFAST, Northern Ireland and CAMBRIDGE, Mass., July 17, 2023 /PRNewswire/ -- Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data, presented interim data from their real-world feasibility study CNS-101 at the Alzheimer's Association International Conference 2023 in Amsterdam, Netherlands.

Key Points: 
  • BELFAST, Northern Ireland and CAMBRIDGE, Mass., July 17, 2023 /PRNewswire/ -- Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data, presented interim data from their real-world feasibility study CNS-101 at the Alzheimer's Association International Conference 2023 in Amsterdam, Netherlands.
  • Purely digital markers are scalable but lack objectivity," said Brian Murphy, PhD, Founder and Chief Scientific Officer of Cumulus.
  • Importantly, the remote data captured in this study was of similar quality to data generated using traditional methods in house at Boston University."
  • Dr. Budson and his team receive funding and other resources from Bristol Myers Squibb and Cumulus Neuroscience.